Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...
OrbusNeich has enrolled its first patient in a two-country proof-of-concept study for its innovative dual-therapy stent.
Neuromodulation devices have been key to Boston Scientific's years-long effort to reverse its lagging fortunes, and now the med tech giant has teamed up with two European nonprofits to promote its treatments for Parkinson's disease and dystonia.
Boston Scientific nabbed a new CE mark that allows one of its esophageal stents to be used to treat narrowing of the esophagus caused by benign scar tissue--another win as the company seeks to restore steady revenue expansion after a years-long slump.
It's a story that could confirm the worst fears of med tech implant wearers at the highest level of U.S. government: Some time during the first half of 2013, hackers reportedly broke into the computer networks of the big three medical device makers, and the breach might have stayed open for "several months."
In 2011, Boston Scientific was listed among 759 other organizations as a victim of attacks by China-based hackers. The report made the cyber cold war public knowledge but companies are still struggling to protect themselves, with the San Francisco Chronicle now reporting Boston Scientific and fellow medtech giants Medtronic and St. Jude Medical have been hacked.
Boston Scientific CEO Mike Mahoney would like to make hay while the sun shines--and for the medical device giant that means widening the gap between it and its big-three rivals, before billion-dollar rainclouds crack open in the untapped U.S. market for renal denervation.
Boston Scientific has been known more in recent years for its struggles rather than its successes. But after years of slashing jobs, reorganizing, and diversifying through a number of acquisitions, the Massachusetts device giant appears to be accelerating a turnaround after glimmers of improvement last year.
On Jan. 2, 2014, a pacemaker was implanted under my right clavicle, with two wire leads snaked through two veins and into my heart. My experience as a patient showed me how limited the true choices are for most U.S. cardiac patients, despite the marketing hype around innovation in the industry.
Medtronic won big in a years-long patent fight with Boston Scientific over its attempt to avoid paying royalties on patents both companies say they hold. The U.S. Supreme Court, in a unanimous ruling, reversed a lower-court decision that would have forced the Minnesota device giant to prove its disputed products could stand on their own, and that royalty payments weren't necessary.